The estimated Net Worth of Bhavesh Ashar is at least $2.63 Million dollars as of 2 February 2024. Mr Ashar owns over 8,056 units of SpringWorks Therapeutics stock worth over $2,248,234 and over the last 4 years he sold SWTX stock worth over $381,371.
Mr has made over 1 trades of the SpringWorks Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 8,056 units of SWTX stock worth $381,371 on 2 February 2024.
The largest trade he's ever made was selling 8,056 units of SpringWorks Therapeutics stock on 2 February 2024 worth over $381,371. On average, Mr trades about 1,007 units every 0 days since 2021. As of 2 February 2024 he still owns at least 58,154 units of SpringWorks Therapeutics stock.
You can see the complete history of Mr Ashar stock trades at the bottom of the page.
Bhavesh Ashar is the Chief Commercial Officer at SpringWorks Therapeutics.
Mr Ashar is 55, he's been the Chief Commercial Officer of SpringWorks Therapeutics since . There are 9 older and 9 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.
Bhavesh's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD, CT, 06902.
Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves..., and Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
SpringWorks Therapeutics executives and other stock owners filed with the SEC include: